120: The Pancreas - Our Most Underrated Metabolic Organ & Why Its Health is Vital w/ Dr. Ben Bikman

Bikman uses fasting as the prime example of the insulin-glucagon push-pull system. He explains that during fasting, blood glucose falls, insulin drops, and glucagon rises. This shift not only maintains blood glucose via glycogenolysis and gluconeogenesis but also increases lipolysis and ketone production. He emphasizes that this natural metabolic flexibility is lost in insulin resistance, where insulin stays high and glucagon cannot do its job, trapping the body in storage mode. By deliberately incorporating fasting, individuals can restore this flexibility, reduce the burden on beta cells, and protect the exocrine pancreas via improved insulin signaling. He ties this to the broader theme that lifestyle habits directly affect both sides of the pancreas, and fasting is a key tool to maintain the balance.

Bikman repeatedly warns that diets heavy in refined carbohydrates and constant snacking keep insulin elevated. He explains that insulin is the body's storage manager, promoting fat storage and inhibiting lipolysis. Over time, cells become resistant, forcing the pancreas to work harder. This not only leads to type 2 diabetes but also, via the portal system, can cause exocrine atrophy because insulin's trophic effect is disrupted. He contrasts this with a diet that allows insulin to fall between meals, which preserves metabolic flexibility. The practical advice is to eat meals that are satiating and low in refined carbs, and to avoid grazing. This aligns with the fasting protocol but focuses on food quality.

Bikman mentions that in cases of chronic pancreatitis or cystic fibrosis, the exocrine tissue is destroyed, causing fat malabsorption. He states that 'pancreatic enzyme replacement therapy becomes essential just for the person to survive.' While he doesn't detail brands or regimens, he underscores the critical nature of this therapy. This is a medical protocol, not a lifestyle one, but it fits the 'protocol' category as a specific action for a specific condition. He also implies that diabetics with unexplained GI symptoms might benefit from evaluation for EPI, given the bidirectional damage.

Dr. Bikman emphasizes that the pancreas is unique in the body as an organ that both produces hormones to regulate nutrient metabolism and produces the enzymes to digest those same nutrients. He notes that 98% of the pancreatic mass is exocrine, yet most attention goes to the 1-2% endocrine islets. The blood flow from islets to exocrine tissue creates a portal system, meaning insulin and other hormones directly bathe the exocrine cells before entering general circulation. This anatomical arrangement underscores the functional interdependence: insulin supports acinar cell growth and enzyme synthesis, while somatostatin restrains enzyme secretion. In disease, damage to one side inevitably affects the other—pancreatitis often leads to diabetes, and diabetes can cause exocrine atrophy. This holistic view reframes pancreatic health as a unified metabolic priority, not two separate issues.

Bikman describes how the islets of Langerhans are heavily vascularized, and the blood leaving them does not immediately return to the heart; instead, it flows into the surrounding exocrine tissue. This means that hormones like insulin, glucagon, somatostatin, and pancreatic polypeptide reach the acinar cells at high concentrations before being diluted in the systemic circulation. Insulin, for instance, promotes acinar cell growth and enzyme synthesis. Somatostatin inhibits enzyme secretion. This local regulation ensures that digestive enzyme release is finely tuned to the metabolic state. Disruption of this portal communication—such as in insulin deficiency—leads to exocrine atrophy, contributing to malnutrition in diabetics. This insight challenges the siloed medical approach and suggests that treating diabetes should also consider digestive health.

Bikman briefly mentions that pancreatic polypeptide is one of the lesser-known hormones from the endocrine pancreas, alongside somatostatin and ghrelin. He states that it contributes to satiety signaling and that 'this is one of the hormones that may be leveraged in future satiety-focused drug therapies to help with weight loss.' While he doesn't elaborate on mechanisms, the implication is that enhancing pancreatic polypeptide activity could reduce hunger. This is notable because current blockbuster weight-loss drugs like semaglutide are GLP-1 receptor agonists; a pancreatic polypeptide analog could offer an alternative pathway. He also notes that disruptions in its signaling can contribute to overeating, linking low levels to increased hunger. This positions pancreatic polypeptide as a potential therapeutic target for metabolic disease.

Bikman explains that insulin acts as a growth factor for the acinar cells of the exocrine pancreas, supporting their maintenance and enzyme synthesis. In type 1 diabetes, where insulin production is absent, or in advanced type 2 diabetes with significant beta-cell failure, the lack of local insulin action leads to atrophy of the exocrine tissue. This results in reduced secretion of digestive enzymes, causing malabsorption, particularly of fats. He notes that this is a practical lesson: lifestyle habits that preserve insulin sensitivity and beta-cell function also protect digestive health. The bidirectional damage means that a patient with diabetes may suffer from unexplained gastrointestinal symptoms due to exocrine insufficiency, which is often overlooked. This insight advocates for screening exocrine function in diabetics and reinforces the need for metabolic control to prevent digestive complications.

Bikman describes somatostatin as a 'babysitter' or 'metabolic brake pedal' that prevents insulin and glucagon from spiking too high. Released from delta cells, somatostatin acts locally on neighboring beta and alpha cells to dampen their secretion. This paracrine fine-tuning ensures that the body doesn't overshoot in either direction—too much insulin would cause hypoglycemia, too much glucagon would cause hyperglycemia. He also notes that somatostatin restrains exocrine enzyme secretion, further integrating the two pancreatic functions. Disruption of somatostatin signaling could contribute to the erratic hormone levels seen in diabetes. This highlights the islet as a complex micro-organ where multiple cell types communicate to maintain homeostasis, not just a binary insulin/glucagon system.